Human papillomavirus vaccine intent and uptake among female college students

Journal of American College Health

Volumn 60, Issue 2, 2012, Pages 151-161

  Patel, Divya A ^a   Zochowski, Melissa ^b   Peterman, Stephanie ^c   Dempsey, Amanda F ^b   Ernst, Susan ^c   Dalton, Vanessa K ^b  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^c UNIVERSITY OF MICHIGAN   (United States)

Author keywords

cervical cancer; human papillomavirus; vaccination; vaccine acceptability; young adult

Indexed keywords

WART VIRUS VACCINE;

ADOLESCENT; ADULT; ARTICLE; ATTITUDE TO HEALTH; BEHAVIOR; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; ECONOMICS; FEMALE; HEALTH SERVICE; HUMAN; PATIENT ATTITUDE; PSYCHOLOGICAL ASPECT; RANDOMIZED CONTROLLED TRIAL; STATISTICS; STUDENT; UNITED STATES; UNIVERSITY;

ADOLESCENT; FEMALE; HEALTH KNOWLEDGE, ATTITUDES, PRACTICE; HUMANS; INTENTION; MICHIGAN; PAPILLOMAVIRUS VACCINES; PATIENT ACCEPTANCE OF HEALTH CARE; STUDENT HEALTH SERVICES; STUDENTS; UNIVERSITIES; YOUNG ADULT;

EID: 84857227396     PISSN: 07448481     EISSN: 19403208     Source Type: Journal    
DOI: 10.1080/07448481.2011.580028     Document Type: Article

References (35)

1. Weinstock H, Berman S, Cates W Jr. Sexually transmitted diseases among American youth: Incidence and prevalence estimates, 2000. Perspect Sex Reprod Health. 2004;36:6-10. (Pubitemid 38258322)
2. Bosch FX, Lorincz A, Munoz N, Meijer CJ, Shah KV. The causal relation between human papillomavirus and cervical cancer. J Clin Pathol. 2002;55:244-265. (Pubitemid 34293391)
3. zur Hausen H. Papillomaviruses and cancer: From basic studies to clinical application. Nat Rev Cancer. 2002;2:342-350. (Pubitemid 37328947)
4. Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010. CA Cancer J Clin. 2010;60:277-300.
5. Gillison ML, Chaturvedi AK, Lowy DR. HPV prophylactic vaccines and the potential prevention of noncervical cancers in both men and women. Cancer. 2008;113(suppl 10):3036-3046.
6. Markowitz LE, Dunne EF, Saraiya M, Lawson HW,Chesson H, Unger ER. Quadrivalent human papillomavirus vaccine: Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep. 2007;56(RR-2):1-24.
7. FDA licensure of quadrivalent human papillomavirus vaccine (HPV4, Gardasil) for use in males and guidance from the Advisory Committee on Immunization Practices (ACIP). MMWR Morb Mortal Wkly Rep. 2010;59:630-632.
8. US Food and Drug Administration. FDA: Gardasil approved to prevent anal cancer.Available at: Http://www.fda.gov/downloads/ BiologicsBloodVaccines/ Vaccines/ApprovedProducts/UCM247722 pdf. Published 2010. Accessed December 27, 2011.
9. US Food and Drug Administration. FDA approves new vaccine for prevention of cervical cancer. Available at: Http://www.fda.gov/NewsEvents/Newsroom/ PressAnnouncements/ ucm187048.htm. Published 2009. Accessed July 13, 2010.
10. Villa LL, Costa RL, Petta CA, et al. High sustained efficacy of a prophylactic quadrivalent human papillomavirus types 6/11/16/18 L1 virus-like particle vaccine through 5 years of followup. Br J Cancer. 2006;95:1459-1466. (Pubitemid 44863348)
11. Paavonen J, Jenkins D, Bosch FX, et al. Efficacy of a prophylactic adjuvanted bivalent L1 virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women: An interim analysis of a phase III double-blind, randomised controlled trial. Lancet. 2007;369:2161-2170. (Pubitemid 46977438)
12. Paavonen J, Naud P, Salmeron J, et al. Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): Final analysis of a double-blind, randomised study in young women. Lancet. 2009;374:301-314.
13. Jain N, Euler GL, Shefer A, Lu P, Yankey D, Markowitz L. Human papillomavirus (HPV) awareness and vaccination initiation among women in the United States, National Immunization Survey-Adult 2007. Prev Med. 2009;48:426-431.
14. National, state, and local area vaccination coverage among adolescents aged 13-17 years-United States, 2008. MMWR Morb Mortal Wkly Rep. 2009;58:997-1001.
15. Zimet GD, Liddon N, Rosenthal SL, Lazcano-Ponce E, Allen B. Chapter 24: Psychosocial aspects of vaccine acceptability. Vaccine. 2006;24(suppl 3):S3/201-209.
16. Moscicki AB. Impact of HPV infection in adolescent populations. J Adolesc Health. 2005;37(suppl 6):S3-S9.
17. Ho GY, Bierman R, Beardsley L, Chang CJ, Burk RD. Natural history of cervicovaginal papillomavirus infection in young women. N Engl J Med. 1998;338:423-428. (Pubitemid 28135669)
18. Partridge JM, Hughes JP, Feng Q, et al. Genital human papillomavirus infection in men: Incidence and risk factors in a cohort of university students. J Infect Dis. 2007;196:1128-1136. (Pubitemid 47580267)
19. Crosby R, Schoenberg N, Hopenhayn C, Moore G, Melhan W. Correlates of intent to be vaccinated against human papillomavirus: An exploratory study of college-aged women. Sex Health. 2007;4:71-73.
20. Allen JD, Mohllajee AP, Shelton RC, Othus MK, Fontenot HB, Hanna R. Stage of adoption of the human papillomavirus vaccine among college women. Prev Med. 2009;48:420-425.
21. Gerend MA, Magloire ZF. Awareness, knowledge, and beliefs about human papillomavirus in a racially diverse sample of young adults. J Adolesc Health. 2008;42:237-242.
22. Boehner CW, Howe SR, Bernstein DI, Rosenthal SL. Viral sexually transmitted disease vaccine acceptability among college students. Sex Transm Dis. 2003;30:774-778. (Pubitemid 37229488)
23. Jones M, Cook R. Intent to receive an HPV vaccine among university men and women and implications for vaccine administration. J Am Coll Health. 2008;57:23-32.
24. Azjen I. The theory of planned behavior. Organ Behav Hum Decis Process. 1991;502:179-211.
25. The SAS Institute. SAS for Windows. Version 9.1 ed. Cary, NC: SAS Institute; 2003.
26. Copeland G, Datta SD, Spivak G, Garvin AD, Cote ML. Total burden and incidence of in situ and invasive cervical carcinoma in Michigan, 1985-2003. Cancer. 2008;113(suppl 10):2946-2954.
27. Dempsey AF, Zimet GD, Davis RL, Koutsky L. Factors that are associated with parental acceptance of human papillomavirus vaccines: A randomized intervention study of written information about HPV. Pediatrics. 2006;117:1486-1493. (Pubitemid 46071374)
28. Davis K, Dickman ED, Ferris D, Dias JK. Human papillomavirus vaccine acceptability among parents of 10-to 15-year-old adolescents. J Low Genit Tract Dis. 2004;8:188-194. (Pubitemid 38859373)
29. Licht AS, Murphy JM, Hyland AJ, Fix BV, Hawk LW, Mahoney MC. Is use of the human papillomavirus vaccine among female college students related to human papillomavirus knowledge and risk perception? Sex Transm Infect. 2010;86(1):74-78.
30. Humiston SG, Rosenthal SL. Challenges to vaccinating adolescents: Vaccine implementation issues. Pediatr Infect Dis J. 2005;24(suppl 6):S134-S140. (Pubitemid 40840110)
31. National Foundation for Infectious Diseases. Adolescent Vaccination: Bridging From a Strong Childhood Foundation to a Healthy Adulthood. Bethesda, MD: National Foundation for Infectious Diseases; 2005. Available at: Http://www.nfid.org/pdf/publications/adolescentvacc.pdf. Accessed January 19, 2007.
32. Conroy K, Rosenthal SL, Zimet GD, et al. Human papillomavirus vaccine uptake, predictors of vaccination, and selfreported barriers to vaccination. J Womens Health (Larchmt). 2009;18:1679-1686.
33. FUTURE II Study Group. Prophylactic efficacy of a quadrivalent human papillomavirus (HPV) vaccine in women with virological evidence of HPV infection. J Infect Dis. 2007;196:1438-1446.
34. Markowitz LE, Sternberg M, Dunne EF, McQuillan G, Unger ER. Seroprevalence of human papillomavirus types 6, 11, 16, and 18 in the United States: National Health and Nutrition Examination Survey 2003-2004. J Infect Dis. 2009;200:1059-1067.
35. Aral SO, Holmes KK. Social and behavioral determinants of the epidemiology of STDs: Industrialized and developing countries. In: Holmes KK, Sparling PF, Mardh P, et al, eds. Sexually Transmitted Diseases. 3rd ed. New York, NY: McGraw-Hill; 1999: 39-76.